Profiling and Targeting Epigenetic Marks to Improve Diagnosis and Therapeutic Approaches i
Investigators have recently shown that epigenetic remodelling enzymes, such as HDAC inhibitors, are feasible drugs in HNC (8, 9). Preliminary data are indicating some deregulated epigenetics marks suggesting the corresponding histone modifiers as possible targets for the treatment of HNC, providing an attractive and fe
| Condition(s) | Head and Neck Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Investigators have recently shown that epigenetic remodelling enzymes, such as HDAC inhibitors, are feasible drugs in HNC (8, 9). Preliminary data are indicating some deregulated epigenetics marks suggesting the corresponding histone modifiers as possible targets for the treatment of HNC, providing an attractive and feasible option to build upon. Our overarching hypothesis is that unique histone marks distinguish HPV+ and HPV- HNC and that specific histone modifiers are novel mediators of HNC tumorigenesis in an HPV specific manner |
| Who can participate | Inclusion Criteria:• Age: Adults aged ≥ 18 years diagnosed with HNC * Sex: Both male and female * Human papilloma virus (HPV) test: Both positive and negative. * Tumor: primary tumors, treatment naïve, squamous cell carcinoma * Cancer stage: I-IV * Anatomic location: oral cavity, larynx, oropharynx * Tumor fragments not required for diagnostics Exclusion Criteria: * Previous radiotherapy, chemotherapy or immunotherapy for HNC * Unable to provide written informed consent |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | European Institute of Oncology |
| Locations | Milan, MI, Italy |
| Start date | 2024-03-06 |
| NCT ID | NCT06706973 |
| Official listing | https://clinicaltrials.gov/study/NCT06706973 |